Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)
NCT00562159 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 439
Last updated 2017-03-03
Summary
This purpose of this study is to determine the efficacy and safety of a grass sublingual (under-the-tongue) tablet.
Conditions
- Rhinoconjunctivitis
- Rhinitis
- Conjunctivitis
- Allergy
Interventions
- DRUG
-
Placebo sublingual tablet
- BIOLOGICAL
-
SCH 697243
SCH 697243 (2800 Bioequivalent Allergen Units \[BAU\] of Phleum pratense extract, containing approximately 15 mcg Phl p 5), administered sublingually once daily.
- DRUG
-
Loratadine 10 mg Rescue Treatment
Loratadine 10 mg RediTabs tablets were dosed orally once daily as rescue medication among participants with a total symptom score ≥ 4 during the GPS.
- DRUG
-
Olopatadine 0.1% Rescue Treatment
Olopatadine hydrochloride 0.1% ophthalmic solution was administered intraocularly at a dose of 1 drop in each affected eye twice daily as rescue medication for rhinoconjunctivitis, as needed.
- DRUG
-
Mometasone 50 mcg Rescue Treatment
Mometasone furoate monohydrate nasal spray 50 mcg was admininstered intranasally at a dose of 2 sprays in each nostril once daily as rescue medication for rhinoconjunctivitis, as needed.
- DRUG
-
Prednisone 5 mg Rescue Treatment
Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day (maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for rhinoconjunctivitis among participants with a total symptom score of ≥ 4 despite treatment with loratadine and mometasone furoate nasal spray.
- DRUG
-
Albuterol sulfate 108 mcg
Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administed via inhalation at a dose of 2 inhalations every 4 to 6 hours, as needed, as rescue medication for asthma.
- DRUG
-
Fluticasone propionate 44 mcg
Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of two inhalations twice daily, to a maximum dose of 10 inhalations twice daily, as rescue medication for asthma among participants utilizing four or more albuterol sulfate inhalations/day for 2 days for nocturnal asthma or shortness of breath.
- DRUG
-
Prednisone 5 mg
Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day (maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for asthma at the discretion of the investigator for the treatment of asthma exacerbation.
Sponsors & Collaborators
-
ALK-Abelló A/S
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-11-30
- Primary Completion
- 2009-09-30
- Completion
- 2009-09-30
More Related Trials
-
Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)
NCT00978029 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract
NCT00619827 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy-safety Study of Sublingual Immunotherapy With Depigmented-polymerized Pollen Extracts to Treat Rhinoconjunctivitis
NCT00550875 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Recombinant Grass Pollen Allergen Cocktail in the Treatment of Allergic Rhinoconjunctivitis
NCT00309036 ·Status: COMPLETED ·Phase: PHASE3
-
A Study in Adults With Grass Pollen-induced Rhinoconjunctivitis
NCT04881461 ·Status: COMPLETED ·Phase: PHASE3
-
Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis
NCT02245360 ·Status: COMPLETED ·Phase: PHASE3
-
An Exploratory Study of PQ Grass 27600 SU
NCT04687059 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation
NCT00623701 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)
NCT02256553 ·Status: COMPLETED ·Phase: PHASE4
-
Determination of Grass Pollen Allergen Concentration Inducing Rhinoconjunctivitis Symptoms in Subjects Allergic to Grass Pollen in ALYATEC Allergen Exposure Chamber
NCT06104293 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy of AL-53817 Nasal Spray Solution
NCT01454505 ·Status: COMPLETED ·Phase: PHASE1
-
Tolerability of ALK Grass Tablet in Children
NCT00310453 ·Status: COMPLETED ·Phase: PHASE1
-
A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen Rhinoconjunctivitis
NCT00812799 ·Status: UNKNOWN ·Phase: PHASE3
-
Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™
NCT02582073 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen
NCT04891237 ·Status: RECRUITING ·Phase: PHASE3
-
Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis
NCT00955825 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL
NCT03931993 ·Status: COMPLETED ·Phase: PHASE1
-
Long-term Efficacy and Safety Study With Oralgen Grass Pollen
NCT00824447 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies
NCT00599872 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen
NCT05540717 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis
NCT02560948 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial of the ALK Grass Tablet in Subjects With Hayfever
NCT00227279 ·Status: COMPLETED ·Phase: PHASE3
-
Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children
NCT00841256 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)
NCT01469182 ·Status: COMPLETED ·Phase: PHASE3
-
Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense
NCT00501527 ·Status: COMPLETED ·Phase: PHASE2